2. Academic Validation
  3. Bazedoxifene attenuates intestinal injury in sepsis by suppressing the NF-κB/NLRP3 signaling pathways

Bazedoxifene attenuates intestinal injury in sepsis by suppressing the NF-κB/NLRP3 signaling pathways

  • Eur J Pharmacol. 2023 Mar 24;947:175681. doi: 10.1016/j.ejphar.2023.175681.
Xiao Zhang 1,  Wei Ning 1,  Ge Gao 2,  Yong Zhou 3,  Xiang-Bing Duan 2,  Xin Li 2,  Dai Li 4,  Ren Guo 5
Affiliations

Affiliations

  • 1 Phase I Clinical Research Center, Xiangya Hospital, Central South University, Changsha, 410005, China; Laboratory Department, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.
  • 2 Laboratory Department, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.
  • 3 Department of Physiology, School of Basic Medical Science, Central South University, Changsha, 410078, China.
  • 4 Phase I Clinical Research Center, Xiangya Hospital, Central South University, Changsha, 410005, China. Electronic address: [email protected].
  • 5 Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, 410013, China. Electronic address: [email protected].
PMID: 36965746 DOI: 10.1016/j.ejphar.2023.175681
Abstract

Acute inflammatory injury is the primary cause of sepsis, leading to various organ failures. Bazedoxifene (BAZ) has been proven to have anti-inflammatory effects. However, its effects on sepsis-induced intestinal injury are unclear. Here, we demonstrated the beneficial effects of BAZ on intestinal injury and explored the underlying mechanisms using cecal ligation and perforation (CLP)-mediated sepsis mouse model and in vitro cultured intestinal epithelial MODE-K cells. We found that BAZ elevated the survival rate of septic mice and attenuated CLP-triggered intestinal damage. BAZ inhibited intestinal inflammation and restored the impaired intestinal barriers in CLP mice. The mechanistic study in lipopolysaccharide (LPS)/adenosine triphosphate (ATP)-stimulated MODE-K cells showed that BAZ significantly downregulated the expression of NOD-like receptor protein 3 (NLRP3), interleukin-1β (IL-1β), Caspase-1, and gasdermin D (GSDMD), and markedly reduced the phosphorylation of molecules in the nuclear factor kappa B (NF-κB) pathway. Moreover, BAZ prominently rescued the decreased viability of MODE-K cells and reduced Lactate Dehydrogenase (LDH) release upon LPS/ATP challenge. However, BAZ did not affect the inflammasome assembly, as evidenced by the lack of changes in ASC (Apoptosis speck-like protein containing a CARD) speck formation. Our results suggest that BAZ relieves inflammation and intestinal barrier function disruption by suppressing the NF-κB/NLRP3 signaling pathways. Therefore, BAZ is a potential therapeutic candidate for treating intestinal injury in sepsis.

Keywords

Bazedoxifene; Inflammation; Intestinal injury; NF-κB; NLRP3 inflammasome; Sepsis.

Figures
Products